Iovance Biotherapeutics (IOVA) to Release Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.19) per share and revenue of $77.8370 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million for the quarter, compared to analysts’ expectations of $81.61 million. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ:IOVA traded up $0.05 during trading on Wednesday, reaching $4.03. 3,291,304 shares of the stock traded hands, compared to its average volume of 14,921,137. The stock has a 50-day moving average of $3.79 and a two-hundred day moving average of $2.92. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.63. The stock has a market cap of $1.80 billion, a P/E ratio of -3.61 and a beta of 0.69.

Analyst Upgrades and Downgrades

IOVA has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. The Goldman Sachs Group reiterated a “sell” rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. UBS Group raised their target price on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Thursday, March 5th. Truist Financial upgraded shares of Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Finally, Barclays increased their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Iovance Biotherapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.88.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Captrust Financial Advisors increased its holdings in Iovance Biotherapeutics by 13.5% in the 4th quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 5,563 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Iovance Biotherapeutics by 30.6% in the third quarter. BNP Paribas Financial Markets now owns 54,353 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 12,730 shares during the last quarter. Man Group plc bought a new stake in shares of Iovance Biotherapeutics in the 3rd quarter worth about $112,000. CANADA LIFE ASSURANCE Co grew its holdings in Iovance Biotherapeutics by 20.4% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 40,958 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 6,933 shares during the last quarter. Finally, DRW Securities LLC purchased a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $78,000. 77.03% of the stock is currently owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.